Dr. Anne Borgman is an accomplished CMO, business executive, scientific advisor and board director with 20+ years of experience devising clinical development strategies and successfully leading teams to excellence and timely execution in oncology-hematology drug approvals. Dr. Borgman’s strength lies in her ability to organize and galvanize teams to fulfil mission critical business objectives. She is a creative problem solver and developer of human capital. Her broad network, depth of regulatory interactions and experience developing oncology and hematology drugs enables her to quickly synthesize the competitive landscape and collaborate with key stakeholders to forge a strategic path forward in a complex landscape.
Dr. Borgman has led teams to successful approval of several oncology assets. Most recently while Therapeutic Area Head Hematology-Oncology and Vice President at Jazz Pharmaceuticals, she led a successful filing for a recombinant asparaginase using the intensive Real Time Oncology Review process and expanded filings for other hematology-oncology assets. Prior, while Vice President at Exelixis, Inc. she led several successful filings for the lead asset cabozantinib, including a U.S. and European approval in renal cell carcinoma, a U.S. and European approval in hepatocellular carcinoma and a European approval in medullary thyroid carcinoma. Additionally, Dr. Borgman led the filing for an accelerated approval for liposomal vincristine in adult relapsed acute lymphoblastic lymphoma while Chief Medical Officer at Hana Biosciences. Dr. Borgman created the early development strategies for the Bcl-2/Bcl-XL inhibitor (now venetoclax) and veliparib while Global Project Head for Abbott Laboratories.
Sign up to view 6 direct reports
Get started